Physician profile
Luis Haddock
NPI 1073769717
$45,565.90
in general payments reported to CMS, 2019-2025
25 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,707 · 2020: $576 · 2021: $3,528 · 2022: $11K · 2023: $7,754 · 2024: $12K · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $4,040 · Travel and Lodging: $2,055 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,575.50 |
| Food and Beverage | $4,039.97 |
| Travel and Lodging | $2,054.94 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $17,750.31 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $16,786.57 | 2019-2025 | Centurion, Argos, Clareon |
| Regeneron Pharmaceuticals, INC. | $3,546.13 | 2023-2024 | Eylea, Eylea Hd |
| Lumibird Medical INC. | $1,500.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,134.36 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $860.64 | 2019-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $797.16 | 2022-2025 | Syfovre |
| Notal Vision, INC. | $458.29 | 2019-2025 | Foresee Home |
| Eyepoint US, INC. | $387.51 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $352.08 | 2021-2023 | Tecnis Iol |
| Carl Zeiss Meditec, INC. | $293.64 | 2019-2020 | |
| Abbvie INC. | $290.43 | 2023-2025 | |
| Biotissue Holdings INC. | $269.11 | 2023 | |
| Novartis Pharmaceuticals Corporation | $225.26 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.47 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $139.31 | 2025 | |
| Astellas Pharma US INC | $134.95 | 2024-2025 | Izervay |
| Sight Sciences, INC. | $122.07 | 2019 | |
| Eyevance Pharmaceuticals LLC | $109.10 | 2022 | |
| Ivantis, INC | $99.20 | 2020 | |
| Ani Pharmaceuticals, INC. | $50.08 | 2024-2025 | Purified Cortrophin Gel |
| Dutch Ophthalmic, USA | $38.34 | 2021-2024 | Eva, Combined Machine, Tissueblue |
| Harrow Eye, LLC | $32.94 | 2025 | Triesence |
| Biogen, INC. | $27.95 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Haddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.